Prostate Cancer

Fred Saad, MD, FRCS, discusses unanswered questions from the randomized phase 3 SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Alexandra Sokolova, MD, discusses the rationale for ​systematic germline testing in patients with metastatic prostate cancer.

Neeraj Agarwal, MD, discusses the results from the cohort 6 analysis of the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer​.

The United Kingdom’s National Institute for Health and Care Excellence has chosen to not recommend abiraterone acetate with prednisone/prednisolone plus androgen deprivation therapy as a treatment for patients with newly diagnosed, high-risk hormone-sensitive metastatic prostate cancer.

Kim Chi, MD, discusses the utility of liquid biopsy in prostate cancer.

William K. Kelly, DO, discusses the next steps with the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.

Fred Saad, MD, FRCS, discusses unique characteristics of apalutamide compared with other antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

In our exclusive interview, Neeraj Agarwal, MD, discusses the recent FDA approval of olaparib in homologous recombination repair–mutant metastatic castration-resistant prostate cancer.

Alexandra Sokolova, MD, discusses the challenges of germline testing in patients with metastatic prostate cancer. 

Huma Q. Rana, MD, MPH, discusses germline genetic testing in men with advanced prostate cancer.

Fred Saad, MD, FRCS, discusses the safety profile of apalutamide in nonmetastatic castration-resistant prostate cancer.

Alexandra Sokolova, MD, discusses the systematic implementation of a germline testing protocol for patients with metastatic prostate cancer.

The FDA has granted a priority review designation to a new drug application for relugolix as a treatment for patients with advanced prostate cancer.

​Neal D. Shore, MD, FACS, discusses the rationale for conducting the phase 3 HERO trial in advanced prostate cancer.

The addition of apalutamide to androgen deprivation therapy, significantly improved overall survival and metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer.

Alexandra Sokolova, MD, discusses the rationale for systematic implementation of germline testing for patients with metastatic prostate cancer.

Michael J. Morris, MD, discusses factors to consider when deciding among PET tracers in prostate cancer.

William K. Kelly, DO, discusses the design of a phase 1B dose-finding trial that evaluated the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.

Eric A. Klein, MD, discusses challenges with active surveillance in prostate cancer.

The combination of ipatasertib plus abiraterone acetate and prednisone/prednisolone improved radiographic progression-free survival compared with standard treatment plus placebo in patients with metastatic castration-resistant prostate cancer who have PTEN loss.

The first multidisciplinary, consensus-driven framework for genetic testing in prostate cancer was borne out of the 2019 Philadelphia Prostate Cancer Consensus Conference, leading to the creation of comprehensive guidelines regarding the evaluation, management, and implementation therein.

Aaron E. Katz, MD, FACS, discusses the Oncotype DX Genomic Prostate Score assay in patients with prostate cancer.

Mark M. Awad, MD, PhD, discusses the main objectives of the phase 2 GEOMETRY mono-1 study in patients with MET exon 14 skipping (METex14)-mutated non–small cell lung cancer (NSCLC).

A. Oliver Sartor, MD, discusses the design of the REASSURE trial (NCT02141438) in patients with metastatic castration-resistant prostate cancer.

A. Oliver Sartor, MD, discusses the rationale for investigating the sequential use of beta emitters and alpha emitters in metastatic castration-resistant prostate cancer.